



Immune Checkpoint Therapy and Biomarker in Cancer

Guest Editor:

Dr. Hashem O. Alsaab

Department of Pharmaceutics
and Pharmaceutical Technology,
Taif University, Taif 21944, Saudi
Arabia

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Immune checkpoint therapy such as CTLA-4 or PD-1/PD-L1 immune checkpoint inhibitors (ICPs), chemoimmunotherapy, and CART therapy has revolutionized cancer treatment by harnessing the power of the immune system to fight cancer. However, not all patients respond to this therapy, and identifying the right patients is vital to ensure the best possible outcomes. This is where biomarkers come in. Biomarkers are measurable indicators that can help predict the likelihood of a patient responding to a particular therapy. In the case of immune checkpoint therapy, biomarkers can help to identify patients who are most likely to benefit from the therapy, but they can also be used to monitor a patient's response to therapy.

New translational and clinical research on immune checkpoint therapy and biomarkers holds great promise for the treatment of different types of cancer. By identifying the right patients and monitoring their response to therapy, clinicians can ensure that patients receive the most effective treatment possible. As research in this area continues, our goal in this Special Issue is to collect papers on advances in the field of cancer ICPs and biomarkers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)